# MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

> **NCT05255471** · PHASE3 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 200 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Chemotherapy drug

## Key facts

- **NCT ID:** NCT05255471
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2028-01-21
- **Final completion:** 2028-01-21
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255471, "MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05255471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*